Back to top
more

BridgeBio Pharma (BBIO)

(Delayed Data from NSDQ)

$24.88 USD

24.88
1,049,016

+0.55 (2.26%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $24.91 +0.03 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BBIO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for BridgeBio Pharma, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 452 510 837 607 546
Receivables 2 17 20 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 24 22 32 36 23
Total Current Assets 478 549 889 643 569
Net Property & Equipment 12 15 30 20 6
Investments & Advances 0 0 0 0 31
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 26 29 45 0 0
Deposits & Other Assets 23 20 33 24 26
Total Assets 546 623 1,013 704 632
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 11 12 12 9 9
Current Portion Long-Term Debt 0 0 0 1 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 123 98 118 76 39
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 6 8 0 6 4
Total Current Liabilities 144 121 135 96 60
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,727 1,708 1,704 476 92
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 9 27 22 10 4
Minority Interest (Liabilities) 0 -2 1 2 2
Total Liabilities 1,889 1,866 1,880 597 158
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,481 939 842 1,021 848
Retained Earnings -2,561 -1,918 -1,437 -889 -440
Other Equity 11 11 3 49 66
Treasury Stock 275 275 275 75 0
Total Shareholder's Equity -1,343 -1,243 -867 106 474
Total Liabilities & Shareholder's Equity 546 623 1,013 704 632
Total Common Equity -1,343 -1,243 -867 106 474
Shares Outstanding 173.90 149.40 147.10 122.70 123.50
Book Value Per Share -7.72 -8.32 -5.89 0.87 3.84

Fiscal Year End for BridgeBio Pharma, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 452 560 404 517
Receivables NA 2 5 9 11
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 24 23 21 25
Total Current Assets NA 478 588 433 553
Net Property & Equipment NA 12 12 13 14
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 26 27 28 28
Deposits & Other Assets NA 23 19 20 21
Total Assets NA 546 655 504 626
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 11 4 4 4
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 123 91 96 82
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 6 7 6 7
Total Current Liabilities NA 144 106 110 97
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 1,727 1,721 1,719 1,713
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 12 13 18
Minority Interest (Liabilities) NA 0 1 0 0
Total Liabilities NA 1,889 1,850 1,854 1,839
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,481 1,460 1,128 1,107
Retained Earnings NA -2,561 -2,392 -2,215 -2,057
Other Equity NA 11 12 12 12
Treasury Stock NA 275 275 275 275
Total Shareholder's Equity NA -1,343 -1,195 -1,350 -1,213
Total Liabilities & Shareholder's Equity NA 546 655 504 626
Total Common Equity 0 -1,343 -1,195 -1,350 -1,213
Shares Outstanding 175.80 173.90 173.90 161.40 160.50
Book Value Per Share 0.00 -7.72 -6.87 -8.36 -7.56